Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlobalData Plc    DATA   GB00B87ZTG26


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlobalData : Second wave of COVID-19 vaccines unlikely to be required to improve on protection data of first batch of authorized vaccines

10/23/2020 | 01:30pm EST
23 Oct 2020
Second wave of COVID-19 vaccines unlikely to be required to improve on protection data of first batch of authorized vaccines
Posted in Pharma

With the US' Food and Drug Administration's staging an all-day virtual meeting yesterday (22 October) regarding its planned standards for authorizing a COVID-19 vaccine;

Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view:

'In the event at least one of the COVID-19 vaccine frontrunners is granted an FDA Emergency Use Authorization (EUA) before the end of the year, the second wave of vaccines are unlikely to be required to reach a higher efficacy bar than what was discussed yesterday. This is primarily due to the huge market for such vaccines, that the first authorized vaccines will be unlikely to meet demand that even a slightly inferior vaccine could still be authorized. However, it would be best for these second wave vaccines to underscore ideal subpopulations or manufacturing and storage advantages that could underscore uptake.

'Such second wave of vaccines include CureVac's Phase IIa CVnCoV and Sanofi/GlaxoSmithKline's Phase I/II unnamed protein subunit vaccine. Although Novavax's NVX-CoV2373 is in a 10,000-volunteer Phase III trial in the UK, there is still no firm date for a US-based trial. Inovio, which was once a frontrunner, received an FDA partial clinical hold for its planned Phase II/III INO-4800 trial, owing to its delivery device.

'With an authorized vaccine in the market, the FDA may require a noninferiority, head-to-head trial for authorization, but such trials may be hard to stage and so are rarely considered. While matching authorized vaccines' immunogenicity data could be a shortcut to argue for authorization, the differing technologies used by the vaccines could argue against it.

'As for the frontrunners, Johnson & Johnson's Phase III COVID-19 vaccine trial may be designed to collect more specific data compared with its frontrunner competitors. In turn, this could allow the trial to provide more color to inform of the vaccine's utility if granted an EUA by the FDA. However, this potential edge should not be overstated owing to the recent FDA advice highlighted yesterday, which may lead to comparable data gathering benchmarks between the vaccine frontrunners.

'Despite J&J's 60,000-participant Phase III trial starting several months behind Pfizer/BioNTech's and Moderna's respective late-phase trials, the J&J vaccine JNJ-78436735 has managed to catch up to be a competitor. One reason is that the vaccine only needs a single injection, with Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273 requiring two doses.

'On 12 October, it was announced that all JNJ-78436735 dosing has been put on pause following an unexplained illness in a study participant. But it is currently unclear how this would negatively impact the trial's success due to limited public information about the nature of the illness, and such pauses are not surprising in very large vaccine trials.'


GlobalData plc published this content on 23 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 October 2020 17:29:02 UTC

© Publicnow 2020
All news about GLOBALDATA PLC
06:15aGLOBALDATA : Electrified cars exceeding diesels and going mainstream in UK car m..
06:15aGLOBALDATA : China and casualwear cushion the blow for PVH
06:15aGLOBALDATA : Rolls-Royce strengthens position in global naval gas turbine market..
12/03GLOBALDATA : Grab, Gojek seem to set aside rivalry to counter growing competitio..
12/02GLOBALDATA : Lifetime diagnosed prevalent cases of asthma in 7MM set to surpass ..
12/02GLOBALDATA : Bladder cancer therapeutics market projected to exceed $5.5bn by 20..
12/02GLOBALDATA : ENT market set to fully recover from COVID-19 pandemic in 2021 and ..
12/02GLOBALDATA : Following landmark approval, Pfizer and BioNTech can use UK as test..
12/02GLOBALDATA : China to see over 14,400 diagnosed incident cases of acute lymphocy..
12/02GLOBALDATA : UK foodservice to see critical boost should Pfizer's COVID-19 vacci..
More news
Sales 2020 181 M 244 M 244 M
Net income 2020 23,0 M 31,0 M 31,0 M
Net Debt 2020 67,9 M 91,6 M 91,6 M
P/E ratio 2020 94,6x
Yield 2020 1,05%
Capitalization 1 770 M 2 387 M 2 386 M
EV / Sales 2020 10,1x
EV / Sales 2021 9,49x
Nbr of Employees 3 355
Free-Float 26,5%
Duration : Period :
GlobalData Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 1 535,67 GBX
Last Close Price 1 500,00 GBX
Spread / Highest target 16,0%
Spread / Average Target 2,38%
Spread / Lowest Target -20,0%
EPS Revisions
Michael Thomas Danson Chief Executive Officer & Director
Bernard Anthony Cragg Chairman
Graham Charles Lilley Chief Financial Officer, Secretary & Director
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
S&P GLOBAL INC.19.62%78 582
RELX PLC-7.85%45 608
EQUIFAX INC.17.93%20 101